20148 WEBCAST: Taking the Leap With CAR T: Opportunities for Improving Care and Optimizing Cell Therapy in Hematologic Cancers.
The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy.
This activity can be accessed using the following URL: www.peerview.com/EAA
This activity has been designed to meet the educational needs of hematologistoncologists, oncologists, bone marrow transplant (BMT) specialists, BMT nurse specialists, and other clinicians involved in the management of patients with hematologic malignancies.
Upon completion of this activity, participants should be better able to:
- Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies
- Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma
- Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia
This activity is supported by educational grants from Celgene Corporation; Kite, a Gilead Company; and Novartis Pharmaceuticals Corporation.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Chair & Presenter
Michael R. Bishop, MD Director, Cellular Therapy Program Section of Hematology/Oncology University of Chicago Chicago, Illinois
Michael R. Bishop, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Celgene Corporation; Kite Pharma, Inc./Gilead; and Novartis Pharmaceuticals Corporation. Speakers Bureau participant with Kite Pharma, Inc./Gilead. for Novartis Pharmaceuticals Corporation as a part of a steering committee
Frederick L. Locke, MD Co-Leader, Moffitt Immunology Program Vice Chair and Associate Member Department of Blood and Marrow Transplantation and Cellular Immunotherapy Moffitt Cancer Center Tampa,
Florida Frederick L. Locke, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Allogene Therapeutics; The California Institute for Biomedical Research (Calibr); Celgene Corporation; Cellular Biomedicine Group, Inc.; GammaDelta Therapeutics Limited; Kite Pharma, Inc./Gilead; Novartis Pharmaceuticals Corporation; and Wugen. Stock Shareholder in Cellular Biomedicine Group, Inc.
Michael A. Pulsipher, MD Professor of Pediatrics Keck School of Medicine, University of Southern California Section Head, Transplantation and Cellular Therapy Endowed Chair in Transplantation and Cellular Therapy Clinical Research Children's Hospital Los Angeles Cancer and Blood Diseases Institute Los Angeles, California
Michael A. Pulsipher, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Novartis Pharmaceuticals Corporation. Honorarium from Bellicum Pharmaceuticals, Inc. from Miltenyi Biotec in the form of study support.
Carmine DeLuca PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Providership, Credit, and Support This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians. The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Hours of Participation for Allied Health Care Profession,
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.